May 17, 2016 | Infographic, Research Partnership
Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.
Did you know that last year Research Partnership conducted over 250 projects in over 55 countries, including 35 emerging markets?
Download the infographic: http://www.researchpartnership.com/news/2016/03/infographic-corporate/?utm_source=Research%20Partner…
This content was provided by Inizio
Latest Content from Inizio
Pegasus scoops the much-coveted “Consultancy of the Year” prize at the PR Week Awards 2014
In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in…
As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn’t…
Brighton-based independent healthcare specialist continues to showcase its digital expertise with shortlist nomination
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.
In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with…
Pegasus, the UK’s leading independent health communications consultancy, picked up the much coveted ‘Consultancy of the Year’ award at last week’s Communiqué Awards 2014, fighting off stiff competition from the…
If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to…
Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
